CRDF Cardiff Oncology Inc.

2.47
-0.06  -2%
Previous Close 2.53
Open 2.5
Price To Book 5.37
Market Cap 34,815,482
Shares 14,095,337
Volume 833,877
Short Ratio
Av. Daily Volume 676,844
Stock charts supplied by TradingView

NewsSee all news

  1. Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

    SAN DIEGO, May 29, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

  2. Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

    SAN DIEGO, May 28, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

  3. Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer

    SAN DIEGO, May 19, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

  4. Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

    SAN DIEGO, May 13, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 efficacy data due at EHA June 11-14, 2020.
Onvansertib (PCM-075) (EHA)
Acute Myeloid Leukemia (AML)
Phase 2 biomarker data were to be presented at AACR April 24-29, 2020. Postponed due to COVID-19.
Onvansertib (PCM-075) and Zytiga
Prostate cancer
Phase 1b/2 released April 28, 2020 - 3/7 partial responses. Further presentation at ASCO May 29, 2020 noted 4/9 ORR.
Onvansertib, Folfiri and Avastin (bevacizumab)
KRAS-Mutated Colorectal Cancer

Latest News

  1. Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

    SAN DIEGO, May 29, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

  2. Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

    SAN DIEGO, May 28, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

  3. Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer

    SAN DIEGO, May 19, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,

  4. Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

    SAN DIEGO, May 13, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options,